Abstract-Vascular endothelial growth factor (VEGF) is known to induce the release of nitric oxide (NO) from endothelial cells. However, the effect of NO on VEGF synthesis is not clear. Accordingly, the effect of endogenous and exogenous NO on VEGF synthesis by rat vascular smooth muscle cells (VSMCs) was investigated. Two in vitro models were used:
V ascular endothelial growth factor (VEGF; VEGF-A) induces proliferation of endothelial cells and increases permeability of the vessel wall. VEGF-A belongs to a group of related growth factors that also includes VEGF-B, VEGF-C, and placenta-derived growth factor (PlGF). 1 The physiological activity of VEGF-A is exerted via the specific tyrosine kinase receptors VEGFR-1 (flt-1) and VEGFR-2 (flk1/KDR) present particularly on endothelial cells. 2, 3 VEGF-A is produced by different cell types, including vascular smooth muscle cells (VSMCs), macrophages, fibroblasts, tumor cells, and endothelial cells. 1,4 -10 The expression of several known VEGF-A isoforms is induced by hypoxia; growth factors, including transforming growth factor-␤, basic fibroblast growth factor, and platelet-derived growth factor; and cytokines, among them interleukin (IL)-1␤ and IL-6. 6 -10 It has recently been demonstrated that the physiological effects of VEGF-A are mediated in part by endotheliumderived nitric oxide (NO). [11] [12] [13] Previous studies have shown that enhancement of vascular NO activity after balloon angioplasty suppresses neointimal hyperplasia, an effect that has been ascribed to the inhibitory influence of NO on VSMC growth. 14, 15 However, it is also possible that NO (through VEGF) might enhance endothelial regeneration, thereby reducing restenosis.
The phosphorylation of the flk-1 receptor induces NO release, followed by activation of ERK-1/2 kinase in endothelial cells. 13 The VEGF-dependent release of NO and angiogenic activity of VEGF-A is blocked by tyrosine kinase inhibitors 16, 17 as well as by N -nitro-L-arginine methyl ester (L-NAME), 16, 17 an NO synthase (NOS) inhibitor. The vital role of NO has been demonstrated in eNOS knockout mice, in which angiogenesis is impaired. 18 Furthermore, the circulat-ing inhibitor of NOS asymmetric dimethylarginine (ADMA) impairs angiogenesis 19 ; its elevation in hypercholesterolemia and atherosclerosis may explain the impairment of angiogenesis in these diseases. 20 Recently it was demonstrated that NO donors inhibit VEGF expression in rat VSMCs, although inhibition occurs at pharmacological concentrations of NO donors. 21, 22 In contrast, exogenous NO donors had a stimulatory effect on VEGF synthesis by certain tumor cell lines. 23 Therefore, the physiological effect of endogenous NO on VEGF expression has not been clarified.
Accordingly, we performed this study to determine the effects of endogenous and exogenous NO on VEGF synthesis.
Methods
Reagents DMEM F-12 medium and FCS were purchased from Gibco BRL, and the Total RNA Extraction Kit, Tth DNA polymerase, pSV␤gal plasmid, and TFx-50 liposomes from Promega. Primers were synthesized by TIBMOLBIOL or ARK. Lactate dehydrogenase (LDH) assay was obtained from Wako; reagents for nonradioactive hybridization were obtained from Boehringer Mannheim; and all other chemicals were purchased from Sigma. VEGF concentration was measured by an ELISA kit for mouse VEGF (R&D) that also recognizes rat VEGF.
Plasmid Isolation
The pKecNOS expression plasmid, with kanamycin resistance gene and containing 4.2 kb of bovine endothelial cNOS cDNA, driven by cytomegalovirus (CMV) promoter, was kindly provided by Dr Thomas Michel (Boston, Mass). The plasmids were amplified in Escherichia coli and isolated with Qiagen Endo-Free plasmid kit, which provides supercoiled plasmid with Ͻ1 ng of LPS/mL plasmid solution. The DNA purity was confirmed spectrophotometrically and by agarose electrophoresis.
The following control plasmids were used: pSV␤gal expression plasmid (contains bacterial ␤-galactosidase gene under the control of the SV40 promoter), pCISGTPCH plasmid (contains GTP cyclohydrolase I cDNA driven by the CMV promoter, kindly provided by Drs Edith Tzeng and Timothy Billiar, Pittsburgh, Pa), and pi-NOSCAT plasmid (containing the CAT gene under the control of the rat inducible NOS [iNOS] promoter, kindly provided by Dr Josef Pfeilschifter, Frankfurt am Main, Germany).
Cell Culture
VSMCs were isolated by collagenase digestion of rat thoracic artery and cultured in DMEM F-12 with 5% FCS at 37°C in an atmosphere of 5% CO 2 . Cells of the 5th to 10th passages were used for experiments.
Experimental Procedure

Induction of iNOS Expression
The cells were cultured to full confluence and then placed in DMEM F-12 medium with 0.5% FCS for 24 hours (the presence of a low concentration of FCS is necessary to stabilize VEGF released into the medium). Subsequently, the cells were exposed to IL-1␤ (10 ng/mL) for 24 hours. In some experiments, the cells were exposed to IL-1␤ in the presence of the NOS inhibitor L-NAME (2 to 5 mmol/L) or the GTP cyclohydrolase I inhibitor diaminohydroxypyrimidine (DAHP; 2.5 to 5 mmol/L). Some cells exposed to L-NAME or DAHP for 24 hours were also supplemented with L-arginine (10 mmol/L) or tetrahydrobiopterin (BH 4 ; 100 mol/L), respectively.
Alternatively, cells were treated with sodium nitroprusside (SNP), K 4 Fe(CN) 6 , or K 3 Fe(CN) 6 (10 or 100 mol/L) for 48 hours.
Transfection of VSMCs
For the purpose of gene transfection, cells were cultured in DMEM F-12 with 5% FCS to 50% to 70% confluence. Two liposomes were used for these experiments. The Maxifectin liposome (kindly provided by Dr Andrey Surovoy, Rottenburg, Germany) was used for transfection in the presence of 5% serum, and the Tfx-50 lipotransfection was performed in the absence of serum. Initially, experiments were performed with Maxifectin liposome, and later, all experiments were repeated with Tfx-50 reagent.
Maxifectin lipotransfection: The VSMCs at 50% to 70% confluence were transfected with 1 g of plasmid DNA/30-mm well. The DNA was mixed with 2 L of Enhancer and 10 L of Maxifectin in 200 L of binding buffer (10 mmol/L HEPES, 0.9% NaCl, pH 7.4). After a 20-minute incubation period, the transfection mixture was added to cells covered with 1.8 mL of fresh DMEM F-12 with 5% FCS. The cells were exposed to the transfection mixture for 24 to 48 hours.
Tfx-50 lipotransfection: Plasmid DNA (2.5 g) was mixed with 1 mL of DMEM F-12 without serum, and Tfx-50 was added in a proportion of 2:1 according to the manufacturer's protocol. After 15 minutes of incubation at room temperature, the transfection mixture was poured onto the cells. After 1 hour of incubation at 37°C, 1 mL of DMEM F-12 with 10% FCS was added to the cells, and the VSMCs were incubated up to 24 or 48 hours.
The following experimental groups were established: control cells, which were not transfected; cells treated with liposomes only; cells stimulated with LPS (100 ng/mL) in the presence or absence of liposomes; and cells transfected with pKecNOS, pSV␤al, plSGTPCH, or piNOSCAT plasmid. The pKecNOS-transfected cells were additionally treated with BH 4 (100 mol/L) and/or L-NAME (2 mmol/L).
Measurement of VEGF and NO Synthesis
VEGF synthesis by control, transfected, or IL-1␤-treated cells was measured by ELISA in the medium collected 24 or 48 hours after stimulation.
The generation of NO was detected by Griess reaction 24 for the cells treated with IL-1␤. The more sensitive fluorometric method (detects nitrite at 0.07 to 10 mol/L) 25 was used for estimation of NO 2 Ϫ generation by transfected VSMCs.
Expression of VEGF and iNOS mRNA
Isolation of RNA
Total cellular RNA was isolated from VSMCs according to the method of Chomczynski and Sacchi 26 with a Total RNA Extraction Kit. The RNA concentration and purity were assessed spectrophotometrically by the optical density measured at 260/280 nm. RNA was diluted in RNase-free water and kept at Ϫ70°C.
Primers
The iNOS-specific primers (see the Table) were used to generate a 384-bp product. The primers for VEGF (Table) generated different products, depending on the kind of VEGF isoform expressed, namely a 431-bp product for VEGF 120 (the rat equivalent of human VEGF 121 ), 563 bp for VEGF 164 , and 635 bp for VEGF 188 . Primers for the rat GAPDH (Table) (housekeeping, reference gene) were used to produce a 452-bp product as a control for RNA isolation and amplification.
Reverse Transcription-Polymerase Chain Reaction
A qualitative analysis of mRNA expression was performed by means of reverse transcription-polymerase chain reaction (RT-PCR) assay 
Sequence of Primers Used for iNOS, VEGF, and GAPDH RT-PCR
Nonradioactive Dot-Blot Hybridization
Hybridization with antisense, digoxigenin-labeled VEGF DNA probe generated during 1-primer PCR was performed in a Micro-4 Hybridization oven (Hybaid). Nylon membranes with bound RNA (10 g of each sample) were prehybridized for 2 hours at 42°C in a high-SDS hybridization buffer (7% SDS, 5ϫSSC, 1% blocking reagent, 50% formamide, pH 7.0). After that, the digoxigeninlabeled probes were added to a hybridization buffer. The concentrations of probes were established in 20 to 30 ng/mL buffer. Hybridization was performed overnight at 42°C. The next day, the membranes were washed twice with 2ϫSSC, 0.1% SDS at room temperature, followed by a 2-fold wash with 0.1ϫSSC, 0.1% SDS at hybridization temperature and blocked with excess amounts of 1% blocking reagent. Immunodetection was performed at room temperature for 1.5 hours with alkaline phosphatase-labeled antidigoxigenin antibody (1:3000 to 1:5000 stock dilution in 1% blocking reagent). The hybridization was revealed by overnight reaction with the alkaline phosphatase substrate NBT/X-phosphate diluted in buffer (Tris-HCl 100 mmol/L, NaCl 100 mmol/L, MgCl 2 50 mmol/L, pH 9.5).
Protein Estimation
The cells were washed twice with PBS, scraped off, and lysed with NaOH (1 mol/L), and total protein was estimated by the Lowry method. 27 
Estimation of Cell Viability
The cell viability was assessed by LDH release assay according to the vendor's protocol.
Statistical Methods
Data are presented as meanϮSD. Statistical evaluation was done with ANOVA followed by Tukey's test. A value of PϽ0.05 was accepted as statistically significant.
Results
VEGF Synthesis in IL-1␤-Stimulated VSMCs Is Decreased by NOS Inhibitors
The expression of iNOS and VEGF mRNA was induced by IL-1␤ (Figure 1) . In control cells, which were not exposed to IL-1␤, only weak expression of VEGF 164 and VEGF 120 isoforms was observed ( Figure 1) ; IL-1␤ upregulated the expression of both isoforms. Twenty-four hours after IL-1␤ stimulation, the expression of the third isoform, VEGF 188 , was also observed (Figure 1) .
Treatment with IL-1␤ induced VSMCs to generate NO ( Figure 2A ) and to secrete significantly more VEGF protein (up to 400 pg/mL) into the medium than control VSMCs (up to 140 pg/mL) ( Figure 2B) , depending on the cell batch ( Figure 2B ). L-NAME inhibited NO production ( Figure 2A ) and reduced IL-1␤-induced VEGF synthesis Ϸ30% to 40% ( Figure 2B) . Similarly, inhibition of NO generation by DAHP ( Figure 3A ) also reduced the synthesis of VEGF by VSMCs ( Figure 3B) .
Supplementation with L-arginine did not significantly enhance NO generation by L-NAME-treated cells (Figure 2A ) or the synthesis of VEGF ( Figure 2B ). Increased VEGF synthesis was observed in cells treated with IL-1␤ and L-arginine ( Figure 2B ). Supplementation of DAHP-treated cells with BH 4 slightly increased NO generation ( Figure 3A ) but strongly upregulated VEGF synthesis ( Figure 3B ). Control cells, when exposed to BH 4 , did not increase VEGF synthesis ( Figure 3B ). Neither L-NAME ( Figure 2B ) nor DAHP ( Figure 3B ) alone significantly influenced basal VEGF synthesis.
Generation of NO by pKecNOS-Transfected VSMCs Results in VEGF Expression and Synthesis
When VSMCs were transfected with pKecNOS, they generated NO and expressed VEGF mRNA, as demonstrated by dot-blot hybridization ( Figure 4A ) and RT-PCR ( Figure 4B ). In control cells or in cells transfected with control plasmids, only weak VEGF expression was observed (Figure 4, A and B) .
The amount of NO generated by pKecNOS-transfected VSMCs ranged from 10 to 100 nmol NO 2 Ϫ /mg cellular protein ( Figure 5A ); the production of NO was inhibited by L-NAME ( Figure 5A ). Significantly lower NO 2 Ϫ concentrations were observed in cells transfected with pSV␤gal ( Figure  5A ), pClSGTPCH I, or piNOSCAT control plasmids as well as in VSMCs treated with 100 ng/mL LPS (data not shown).
Cells transfected with pKecNOS plasmid generated significantly higher amounts of VEGF protein than cells transfected with control plasmids (pSV␤gal, pISGTPCH, or pi-NOSCAT) or treated with liposomes ( Figure 5B ) or LPS (not shown). L-NAME significantly inhibited NO generation by pKecNOS-transfected VSMCs ( Figure 5A ) and reduced VEGF synthesis by these cells ( Figure 5B ).
The transfection procedure did not affect cell viability, as demonstrated by LDH measurements of the conditioned medium (data not shown).
Effect of NO Donors and Ferrocyanides
Incubation of VSMCs with SNP led to accumulation of nitrites in culture medium in concentrations similar to those obtained after IL-1␤ stimulation (up to 30 mol/L). This effect was not observed for 2 structurally similar compounds, potassium ferrocyanide and ferricyanide, that are not NO donors. After 48 hours of incubation with SNP (100 mol/L), VEGF generation by VSMCs was significantly decreased. This inhibitory effect was partially mimicked by ferrocyanide and ferricyanide and was correlated with LDH levels in the conditioned medium (rϭ0.92, PϽ0.003) ( Figure 6 ).
Discussion
Previous studies have shown that VEGF expression is induced in VSMCs by IL-1␤. 28, 29 This cytokine triggers the expression of iNOS and generation of NO by VSMCs. 29 -32 Earlier results from our laboratory revealed that iNOS induction after balloon angioplasty of the rat aorta is followed by VEGF expression. 31 In the present study, we determined that VEGF induction by IL-1␤ was related to iNOS activity in VSMCs. We also determined that expression of transfected endothelial constitutive NOS (ecNOS) gene and its resulting production of NO induces VEGF expression in rat VSMCs. Furthermore, when NO generation by NOS was inhibited by L-NAME or DAHP, VEGF synthesis was concomitantly decreased. Finally, when NO generation was even slightly increased by L-arginine or BH 4 supplementation, VEGF synthesis was also restored. Thus, NO generated by VSMCs appears to exert an autocrine or paracrine effect on VSMCs to enhance VEGF synthesis.
Our results are consistent with previous observations that IL-1␤ may induce the generation of NO 30, 32 or VEGF 28, 29 by smooth muscle cells. However, we show for the first time that NO synthesis augments VEGF expression in these cells. The mechanism by which NO enhances VEGF synthesis is under investigation; our results suggest that NO enhances the transcription or stability of VEGF mRNA.
In our hands, L-NAME completely inhibited NO synthesis and diminished VEGF generation in IL-␤-stimulated VSMCs. However, despite cessation of NO synthesis, the VEGF generation was still higher than in control, untreated cells. This indicates the existence of an additional, NOindependent regulation of VEGF synthesis.
Reactive oxygen intermediates are known to stimulate VEGF synthesis in retinal pigment epithelial cells and in some cancer cells. 33 However, it is not likely that superoxide radicals generated by NOS were responsible for the observed effects. We observed that VEGF was further upregulated in the presence of BH 4 and L-arginine, which are both known to reduce the superoxide generation by NOS. 34 -36 However, BH 4 seems to increase VEGF synthesis partially independently of NO generation. We observed that BH 4 restores or even upregulates VEGF synthesis but not NO generation in VSMCs treated with IL-1␤ or IL-1␤ and DAHP. A similar effect of BH 4 on VEGF synthesis was also observed in VSMCs transfected with ecNOS (data not shown). Thus, the role of BH 4 in regulation of this growth factor synthesis requires further investigation.
Recent studies performed by Tsurumi and coworkers 21 suggested an interaction between VEGF and NO generation in the vessel wall. According to their work, VEGF released by the VSMCs of a damaged artery may stimulate reendothelialization, acting together with NO. This suggestion is consistent with studies showing that VEGF protein 37 or VEGF cDNA transfection 38 inhibits restenosis. However, Tsurumi et al found that VEGF expression was downregulated by a high concentration of NO donors. 21 They suggested that inhibition of VEGF synthesis may occur when endothelial regeneration is finished. 21 Figure 1 . Expression of iNOS and VEGF in rat VSMCs after stimulation with IL-1␤. RNA was isolated at different time points after addition of IL-1␤ (10 ng/mL), and RT-PCR was performed on 500 ng of total RNA. Note that expression of iNOS precedes that of VEGF.
We have also observed an inhibition of VEGF generation by pharmacological doses of NO donors (Reference 22, this study, and a study in preparation). However, the inhibitory effect of SNP can be partially mimicked by the same amounts of chemically related compounds, potassium ferrocyanide and ferricyanide, that are not NO donors. The pharmacological doses of these compounds were cytotoxic for rat VSMCs, as indicated by LDH release, and LDH levels were correlated with the decrease in VEGF generation. Thus, although NO concentration was indeed high in medium of cells treated with SNP, it seems likely that the inhibition of VEGF synthesis was related to the toxicity of cyanides released by SNP and the ferrocyanide and ferricyanide. 39 Other recent studies support our conclusion that NO can upregulate VEGF synthesis. Xiong and coworkers 40 demonstrated in murine RAW264.7 macrophages that NOS inhibitors blocked interferon-␥/LPS-activated VEGF production. 40 In studies performed on tumor cell lines, Chin et al 23 observed that NO donors increased the stability of VEGF mRNA. Increased VEGF synthesis by cancer cells generating NO has also been demonstrated by Ambs and coworkers, 41, 42 and upregulation of both NO and BH 4 synthesis in skin wounds was correlated to increased VEGF production. 43 These results are in accordance with our recent observations demonstrating that endogenously generated NO can upregulate VEGF synthesis in VSMCs. Finally, recent studies reported by Gallacher et al 44 demonstrated that in human VSMCs, the NO donors S-nitro-N-acetyl-penicillamine and SNP increased VEGF expression and synthesis at high concentration, whereas low doses of those NO donors inhibited VEGF generation. 44 The reason for the partial discrepancy between the results of the latter and our study is not yet known. One 
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Nitric Oxide Induces VEGF Synthesismay suggest that the effect of NO donors is slightly different in human than rat VSMCs. However, the NO-dependent upregulation of VEGF synthesis seems to be a general phenomenon, because our recent data (unpublished) indicate that endogenous NO generated by ecNOS-transfected human coronary artery VSMCs induced VEGF synthesis in the same way as it did in rat VSMCs. It is also possible that the effects of NO donors can depend on the cell culture conditions. In the present investigations, we have demonstrated that transfection with pKecNOS plasmid resulted not only in the generation of NO by VSMCs but also in VEGF synthesis in such cells. The existence of such a relationship adds to the understanding of the role of ecNOS-derived NO in the regulation of proliferation of endothelial cells. Although some studies demonstrated that NO may stimulate the proliferation of endothelial cells, [11] [12] [13] 45 others failed to prove such a mechanism or even suggested an inhibitory effect of NO 46 on endothelial proliferation. It is known that transfer of eNOS 14 or iNOS 15 genes resulted in the inhibition of restenosis after balloon angioplasty. The inhibitory activity of NO on VSMC proliferation was suggested to exert this protective effect. 14, 15 However, our recent results also indicate that the upregulation of VEGF synthesis by ecNOS-transfected VSMCs might improve reendothelialization in the denuded arteries. 14, 15 Similarly, L-arginine supplementation after balloon angioplasty of rabbit iliac arteries was demonstrated to be beneficial for healing of endothelium, 47 which according to our results may be related to the increased VEGF synthesis due to the enhanced NO generation.
The observed increase in VEGF synthesis after ecNOS transfection cannot be ascribed to contamination of the plasmid isolation by LPS. In our hands, even high doses of LPS did not induce either iNOS or VEGF expression in rat VSMCs, in accordance with earlier observations. 48 We have also shown that the stimulatory effect of transfection itself on VEGF synthesis is not related to the DNA backbone of the control plasmid used, because we observed similar results with different constructs. The mechanism is not clear, and we may only speculate that some degradation products of plasmid DNA can influence VEGF synthesis.
To conclude, we find that endogenous NO enhances VEGF expression by VSMCs. The induction of VEGF synthesis by NO may be of great importance in the maintenance of vascular homeostasis and in the response to endothelial injury. Because NO and VEGF reciprocally enhance their synthesis, this interaction may play a significant role in reendothelialization after balloon angioplasty or in the angiogenic response to ischemia.
Note Added in Proof
Recently Kimura et al 49 demonstrated that some NO-donors upregulated the activity of the human VEGF promoter in human glioblastoma and hepatoma cells, independently of a cGMPmediated pathway. 
